ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapies

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

ARTBIO-financing-$90M

More Like This

PR Newswire associated0

ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors

PR Newswire associated0

ARTBIO Announces Appointment of Nick Pullen, Ph.D., as Chief Scientific Officer

4BIO Capital co-leads Actithera’s oversubscribed $75.5 million Series A financing

PR Newswire associated0

Blue Earth Therapeutics Ltd announces completion of $76.5M Series A financing to accelerate development of next generation targeted radioligand therapies

EQT Life Sciences leads EUR 93 million oversubscribed Series A round in PanTera, which aims to accelerate global actinium - 225 production

Business Wire logo

AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing

PR Newswire associated0

AtomVie Global Radiopharma and Radiopharm Theranostics Partner to Develop and Manufacture 177Lu-BetaBart Radioantibody for Treatment of Multiple Solid Tumors

Arctic Therapeutics Announces €26.5M Oversubscribed Series A Financing